Dr. Ribas on Immune-Related Adverse Events in Melanoma

Video

In Partnership With:

Antoni Ribas, MD, PhD, professor of medicine, University of California, Los Angeles, director, Tumor Immunology Program, Jonsson Comprehensive Cancer Center, discusses immune-related adverse events (irAEs) in melanoma.

Antoni Ribas, MD, PhD, professor of medicine, University of California, Los Angeles, director, Tumor Immunology Program, Jonsson Comprehensive Cancer Center, discusses immune-related adverse events (irAEs) in melanoma.

With immune checkpoint inhibition, physicians have to be aware of the potential irAEs, which may include autoimmune reactions or inflammatory toxicities, says Ribas. Over time, physicians have become more comfortable with using these agents. As such, physicians have been able to better recognize and manage irAEs with earlier intervention strategies, some of which may include immunosuppressive agents, such as corticosteroids.

In terms of the therapies themselves, single-agent PD-1/PD-L1 therapy shows a lower frequency of irAEs compared with when it is used in combination with CTLA-4 inhibitors. In general, combination immunotherapy shows a higher rate of toxicity, says Ribas. Most recently, the FDA approved the PD-1 inhibitor pembrolizumab (Keytruda) as adjuvant therapy for patients with high-risk stage III melanoma with lymph node involvement following complete resection. Nivolumab (Opdivo) and ipilimumab (Yervoy) also hold indications in this setting.

Related Videos
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute